Biocon has received marketing approval for its pegfilgrastim biosimilar from Japan’s Ministry of Health, Labour and Welfare (MHLW). The approval, confirmed on August 25, 2026, strengthens the company’s biosimilar portfolio in one of Asia’s largest pharmaceutical markets.

Biocon Biologics Ltd., a wholly-owned subsidiary of Biocon, developed and manufactured the product. It serves as a biosimilar to Neulasta®, a registered trademark of Amgen Inc. Global Regulatory Partners Japan acts as the Marketing Authorization Holder on behalf of Biocon.

Commercialisation Strategy

Sandoz K.K. will exclusively promote, sell, and distribute the pegfilgrastim biosimilar in Japan. This partnership model allows Biocon to leverage local distribution networks while focusing on manufacturing and regulatory compliance.

The company stated that this approval reaffirms its commitment to increasing patient access to high-quality and affordable medications globally. The move adds to Biocon’s existing footprint in the Japanese biosimilar sector.

What the Numbers Show

The approval marks a strategic expansion into a regulated high-income market. By securing exclusive distribution rights with Sandoz K.K., Biocon mitigates direct commercial execution risk in Japan while capturing revenue through supply agreements. This structure contrasts with fully integrated launch models, potentially improving margin predictability for this specific asset.

Biocon Limited announced on August 18, 2026, that its U.S. subsidiary received supplemental approval from the Food and Drug Administration (FDA) for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjectors. The regulatory nod covers two dosage strengths: 45 mg/0.5 ml and 90 mg/ml. This development expands the delivery formats available for the drug, which was originally approved by the U.S. FDA on November 29, 2024.

The autoinjector format is designed to support tailored treatment approaches across various care settings and patient needs. By offering a self-administered option, the company aims to improve accessibility for patients managing chronic autoimmune conditions.

Approved dosage strengths

The supplemental approval covers the following delivery configurations:

Therapeutic indications

Yesintek is indicated for the treatment of several autoimmune conditions affecting adult and pediatric patients aged 6 years and older. The approved indications include:

• Moderate to severe plaque psoriasis
• Active psoriatic arthritis
• Moderate to severely active Crohn's disease in adults
• Ulcerative colitis in adults

Portfolio impact

This supplemental approval strengthens Biocon's immunology product portfolio in the United States. The move reaffirms the company's strategy to improve access to affordable medicines globally by diversifying delivery mechanisms for existing therapies.